Vertex forecasts upbeat 2025 revenue on cystic fibrosis treatments demand
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Vertex (VRTX) PT Raised to $459 at Morgan Stanley
February 11, 2025 7:10 AM ESTMorgan Stanley analyst Terence Flynn raised the price target on Vertex (NASDAQ: VRTX) to $459.00 (from $450.00) while maintaining a Equalweight rating.
The analyst comments "VRTX posted a 4Q beat and first time 2025 Rev/expense guidance bracketed consensus. Looking ahead the focus is on... More
